Ingredion's $3.7 Billion Tate & Lyle Bid Is a Bet on the Future of Food Reformulation

Tate & Lyle spent more than 150 years making sugar. Now it is being acquired because it figured out how to take sugar out of food.

On May 14, 2026, Ingredion made a non-binding all-cash offer of 595 pence per share for Tate & Lyle — worth £2.74 billion, or roughly $3.7 billion. Including two permitted dividends, the total value per share reaches 615 pence. That is a 64% premium over where Tate & Lyle's stock was trading the day before. A 64% premium is not a discount entry. It is a statement of conviction. Ingredion has until 5pm London time on June 11, 2026 to make a firm offer under UK Takeover Code Rule 2.7 — or walk away.

If the deal completes, it will create a combined ingredients business worth more than $10 billion. That would make it the largest speciality food ingredient company in the world.

A Company Transformed

To understand why this deal is happening, you need to understand what Tate & Lyle has become.

The company was formed in 1921 from the merger of two historic British sugar businesses. For most of its life it was a bulk commodity processor — sugar, corn syrup, industrial starches. Then in 2021 it sold its Primary Products division, the industrial sweeteners and starches business in the Americas, to private equity firm KPS Capital Partners for $1.3 billion. The commodity business was gone. What remained was a focused speciality ingredients company built around three platforms: sweetening, mouthfeel, and fortification.

The transformation kept going. In November 2024, Tate & Lyle acquired CP Kelco for $1.8 billion. CP Kelco produces pectin, xanthan gum, and nature-based hydrocolloids — the ingredients that give food its texture, body, and stability. That acquisition made Tate & Lyle a genuine leader in texture ingredients at commercial scale.

By the year ended March 31, 2026, Tate & Lyle reported £2.0 billion in revenue from continuing operations. In its FY2025 results, the combined Tate & Lyle and CP Kelco business generated pro forma EBITDA of £446 million, free cash flow of £190 million, and an EBITDA margin of 22.3% — up 200 basis points year-on-year. Net debt to EBITDA stood at 2.2 times, better than the company expected when it bought CP Kelco.

What Ingredion Is Really Buying

Ingredion is not buying a sugar business. It is buying the world's most complete toolkit for food reformulation.

About 70% of Tate & Lyle's products are used by food and drink manufacturers to reduce sugar or calories in their finished products. That figure sits at the intersection of two powerful trends: consumer demand for less sugar, and growing regulatory pressure — from sugar taxes in the UK, EU, and across Asia — that forces manufacturers to reformulate or face cost consequences.

Tate & Lyle's portfolio now spans sweeteners, fibres, starches, proteins, pectin, gums, and texturants — the full set of tools a food company needs to re-engineer a product without losing taste or appeal. CP Kelco's pectin alone appears in dairy, beverages, and confectionery products across the globe.

Ingredion has been building a parallel capability. It launched a $2.4 billion Texture & Healthful Solutions segment in early 2024 and committed $100 million to a new texture ingredients facility in Indianapolis. In its most recent results, Texture & Healthful Solutions delivered 4% volume growth while the rest of the business faced headwinds. The Tate & Lyle acquisition would give Ingredion significant scale in texture and nutrition ingredients overnight, and materially expand its footprint in Europe and Asia.

The Strategic Logic

The speciality ingredients industry is entering a phase of consolidation, and Ingredion is trying to get ahead of it.

The food industry faces a structural reformulation demand. GLP-1 drugs are changing what consumers eat and how much. MAHA regulatory pressure in the US is pushing scrutiny of additives and food quality. Sugar taxes are spreading across Europe, Asia, and Latin America. Ultraprocessed food legislation is being debated in multiple EU member states. Every one of these trends increases demand for ingredients that help manufacturers produce food with less sugar, more fibre, and a cleaner ingredient list.

A supplier that can offer a single-source solution across sweetening, texture, fibre, and mouthfeel — at global scale — has a structural advantage over smaller ingredient companies that only cover part of the problem. This deal is about building the kind of integrated, one-stop reformulation partner that large food companies want as complexity increases.

Ingredion made multiple approaches to Tate & Lyle's board before this bid was publicly disclosed. That history signals this is a strategic priority, not an opportunistic move.

What Happens Next

Ingredion must decide by June 11 whether to convert its non-binding proposal into a firm offer or step back. If it proceeds, the deal will face regulatory review in multiple jurisdictions — UK, US, EU, and likely China, where both companies have operations.

Ingredion generated $944 million in operating cash flow in 2025 and has a market cap of $6.51 billion. Funding a $3.7 billion acquisition alongside integration is achievable but will require careful capital management. Tate & Lyle's balance sheet — net debt to EBITDA at 2.2 times — means the combined entity would not be highly leveraged at close.

If Ingredion walks, Tate & Lyle does not go back to being a cheap stock. A 64% takeover premium at this scale tends to attract other bidders. The question then is who else in the ingredients, food, or private equity space has the appetite and the capital for a £2.74 billion transaction.

The food ingredient sector is entering a new phase. The companies that supply the science behind healthier food are becoming as strategically valuable as the brands that sell it. This deal, if it closes, will accelerate that shift.